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“Life begins at the end of your comfort zone” 
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Food is a recurrent problem in irritable bowel syndrome (IBS) and it is common to 
exclude foods, which could lead to a reduced nutrient intake. Perceived food 
intolerance is very common in IBS, but if specific or more generalized food 
intolerance is the problem is unknown. Incompletely absorbed carbohydrates 
(fermentable oligo-, di-, mono-saccharides and polyols, FODMAPs) can trigger 
gastrointestinal (GI) symptoms, but if an enzyme (?-galactosidase), capable of 
digesting oligosaccharides, is able to relieve meal-related symptoms, or if a diet low 
in FODMAPs is more efficient in reducing symptoms than traditional dietary advice 
is not known. 
Methods: Paper 1: The nutrient intake (from food diaries) in IBS patients was 
compared with a sex-and-age matched population from a Swedish national dietary 
survey. Paper 2: IBS patients completed questionnaires to assess self-reported food 
intolerance and the association with other clinical and demographic variables. Paper 
3: In a randomized, double-blind, placebo-controlled, crossover trial; the effect of ?-
galactosidase on GI symptoms in IBS patients after carbohydrate-rich meals was 
investigated. Paper 4: In a randomized, single-blind, parallel group, four-week trial; 
the effect on IBS symptoms of a low FODMAPs diet was compared with traditional 
dietary advice in IBS.
Main results: The nutrient intake in IBS patients was similar to the Swedish general 
population. Eighty-four percent of IBS patients reported food-related GI symptoms, 
especially after intake of foods rich in incompletely absorbed carbohydrates and fat. 
Self-reported food intolerance was associated with more severe IBS symptoms and 
reduced quality of life. ?-galactosidase was not superior to placebo in reducing GI 
symptoms after carbohydrate-rich meals in IBS patients. Fifty percent in the low 
FODMAPs group responded favorably to the dietary intervention (reduced GI 
symptoms), and 46 % were responders in the group who received traditional dietary 
advice. 
Conclusions: Despite a high degree of self-reported food intolerance in IBS, the 
majority of these patients seem to have adequate nutrient intake. A low FODMAPs 
diet and traditional IBS dietary advice, but not ?-galactosidase capsules, reduce 
symptom burden in patients with IBS.  
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 Bakgrund: Irritable bowel syndrome (IBS) är en vanlig funktionell mag-
tarmsjukdom som kännetecknas av smärta och/eller obehag i magen i kombination 
med avföringsrubbning. Mat är ett återkommande och centralt problem för många 
patienter med IBS, som ofta uppger att de undviker ett eller flera livsmedel, vilket 
kan leda till minskat näringsintag. Upplevd födoämnesintolerans är mycket vanlig i 
patientgruppen men man vet inte om överkänslighet för något enskilt födoämne kan 
påvisas. Man har sett att inkomplett absorberbara kolhydrater, s.k. FODMAPs, kan 
orsaka IBS-symtom, men om ett enzym som kan underlätta upptaget av kolhydrater i 
tunntarmen kan lindra måltidsrelaterade symtom eller om en kost med lågt 
FODMAPs-innehåll medför färre symtom än traditionella kostråd är okänt.  
Metod: För att bedöma hur IBS-patienter äter jämförde vi näringsintaget 
(kostdagböcker) från 187 IBS-patienter med en ålders- och könsmatchad 
kontrollgrupp (384 personer) från en nationell kostundersökning. För att sedan 
undersöka vilka livsmedel som IBS-patienter anser ge mag-tarmsymtom, fyllde 197 
IBS-patienter i frågeformulär, där de specificerade mag-tarmsymtom efter intag av 
56 olika livsmedel. Vi genomförde sedan två behandlingsstudier: Först undersökte vi 
om ett enzym (?-galaktosidas) kunde avhjälpa symtom som uppkom i samband med 
kolhydratrik mat hos 20 IBS-patienter. Efter det undersökte vi hos 75 IBS-patienter 
om en kost med lågt FODMAPs-innehåll är mer effektiv än traditionella kostråd vid 
IBS för att lindra mag-tarmsymtom. 
Resultat: IBS-patienternas näringsintag skiljde sig inte nämnvärt från 
normalbefolkningen, trots att 84 procent av patienterna rapporterade mag-
tarmsymtom efter intag av olika livsmedel och då framför allt efter livsmedel som 
innehåller fett och inkomplett absorberade kolhydrater. Mag-tarmsymtom efter intag 
av kolhydratrika måltider lindrades inte mer av ?-galaktosidas jämfört med placebo. 
Femtio procent av testgruppen svarade positivt (minskade symtom) på låg-
FODMAPs-kosten och 46 % svarade positivt i gruppen som fått traditionella kostråd.  
Slutsatser: Patienter som har IBS äter ungefär som normalbefolkningen i Sverige 
och har som grupp ett adekvat näringsintag. De flesta IBS-patienter upplever att kost 
som innehåller mycket fett och inkomplett absorberbara kolhydrater orsakar symtom. 
Det verkar inte hjälpa IBS patienter att ta ?-galaktosidas i samband med kolhydratrik 
måltid för att lindra mag-tarm-symtom. Emellertid verkar kostråd vara effektivt för 
att minska mag-tarmsymtom vid IBS och de kostråd vi testade bör i framtiden 
sannolikt kombineras i ytterligare studier av deras symtomlindrande egenskaper. 
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Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) 
disorder that affects persons world-wide, and a recent systematic review of 
eighty cross-sectional surveys found a global prevalence of 11.2 % in the 
adult population (with significant geographical differences ranging from 1.1 
% to 45 %) (1). This makes IBS one of the most common GI disorders, and it 
is one of the leading causes for consultations in gastroenterology outpatient 
clinics, as well as in primary care (2). However, a large proportion of subjects 
with the disorder do not seek medical advice (2). IBS is more common in 
women than in men, with a female/male ratio of approximately 2 to 1 (3), and 
the peak prevalence is between the ages of 20 and 30 years (4). 
IBS, which is the most common functional bowel disorder, is characterized 
by abdominal pain and/or discomfort related to abnormal bowel habit 
(diarrhea, constipation or mixed diarrhea and constipation), but with normal 
clinical routine investigations and tests (5). The etiology and pathophysiology 
are only partly understood (6) and available treatment options are limited (7). 
IBS has profound effects on quality of life (8) and is associated with 
substantial costs for the society (9). Unfortunately, there are no available 
objective biomarkers and the diagnostic criteria have changed somewhat over 
the years, which make prevalence figures from different time periods difficult 
to compare. The first diagnostic criteria developed for IBS was the Manning 
criteria from 1978, which included abdominal pain relieved by defecation, 
more frequent stools and/or looser stools with onset of pain, passage of 
mucus per rectum, feeling of incomplete emptying, and abdominal distension 
(10). Later, groups of multinational experts have refined the diagnostic 
criteria for IBS and other functional bowel disorders in the Rome I (11), II 
(12) and III (5) criteria, respectively. In Table 1 the most recent diagnostic 
criteria for IBS, the Rome III criteria, is shown. In order to make a confident 
diagnosis, a limited number of routine investigations are recommended, and 
normal results are expected. Moreover, in order to rule out more severe GI 
diagnoses as an explanation for the symptoms, it is considered essential to 
???????????????????????????????????oms, such as symptom onset after 50 years 
of age, rectal bleeding, recurrent vomiting, fever, and family history of colon 
cancer. The presence of any of these necessitates a more thorough clinical 
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investigation before an IBS diagnosis can be made (2, 13). Based on the 
dominant stool form or consistency, IBS is also subtyped into IBS with 
constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), and 
unsubtyped IBS (IBS-U) (5). 
Table 1. The Rome III Diagnostic Criteria* 
Recurrent abdominal pain or discomfort** at least 3 days per month in the last 3 months 
associated with 2 or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 
* Criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to 
diagnosis. 
** "Discomfort" means an uncomfortable sensation not described as pain. 
 
As stated above, the key symptoms in IBS are abdominal pain and abnormal 
bowel habit, but also other symptoms such as bloating, abdominal distension, 
flatulence, urgency, defecation straining, and feeling of incomplete bowel 
emptying are common (5, 14). The frequency and the intensity of GI 
symptoms vary substantially in IBS patients, and not everybody with 
symptoms seeks medical care for their symptoms. This may have different 
explanations, e.g. frequency or intensity of symptoms, coping abilities, 
cultural differences, and psychosocial factors (15). Besides, as the disorder is 
associated with symptoms such as flatulence, abdominal distension, diarrhea, 
constipation, and urgency to defecate, it is also associated with several taboos 
and embarrassing situations (16). Moreover, patients with IBS also often 
report symptoms related to other parts of the GI tract than the bowel (17), as 
well as multiple extraintestinal symptoms (18, 19). Backache, headache, 
lethargy, urinary symptoms, fibromyalgia, chronic fatigue syndrome, 
sleeping problems, and nausea are examples of comorbid 
symptoms/conditions that may co-exist with IBS (20, 21), and psychological 
co-morbidity is also commonly seen in IBS patients, especially in those who 
seek health care frequently (20, 22). The presence of multiple GI and 
extraintestinal symptoms in combination with typical IBS symptoms actually 
support a diagnosis of IBS (23).  
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The pathophysiology of IBS is incompletely understood, and there seem to be 
several important factors in IBS which could explain the origin and causes of 
symptoms, such as dysregulation of the brain-gut axis, genetic factors, 
psychosocial factors, early family environment, abnormal gut motility and 
sensitivity, impaired gut barrier function, low-grade inflammation and altered 
gut microbiota (24-28). Genetic factors may predispose to the development of 
IBS, but the exact role of genetic factors in IBS is so far not well known (29). 
One of the most widely studied pathophysiologic factors in IBS is visceral 
hypersensitivity, which is found in a substantial proportion of IBS patients, 
(30, 31) but whether this is due to abnormalities in the gut or in the brain, or 
at different sites in different individuals, is not known. The brain-gut axis is 
the constant communication between the central nervous system (CNS) and 
the enteric nervous system (ENS) of the gut. The brain influences the 
functions of the ENS and the gut affects the brain. The symptoms in IBS is 
currently believed to be caused by dysfunction in this communication (28, 
32). Psychological co-morbidity and other psychosocial factors, coping 
abilities, daily hassles, and major life events can precede the onset of IBS and 
influence symptom exacerbation of IBS in susceptible persons (33). Early life 
trauma and abuse increase the risk of developing IBS, and socioeconomic 
status and social learning can influence the development and manifestation of 
illness behavior and symptoms in adults (34, 35). Moreover, IBS has 
traditionally been associated with altered GI motility, and in some patients 
increased frequency and irregular bowel contractions have been seen together 
with affected transit time through the GI tract, and in other patients an 
exaggerated motor response to meal ingestion has been reported (31, 36-38). 
???????????????????????????????????????????????????????????????????????????
as low-grade inflammation in the GI tract and immune activation, impaired 
epithelial barrier function, and altered microbiota composition and function 
in the colon, as well as in other parts of the GI tract (25). Taken together, the 
pathophysiology of IBS is complex and poorly understood and future studies 
need to determine the relative importance of the above mentioned factors, as 
well as how they interact and cause symptoms in patients with IBS. 
 
 
The main function of the GI tract is to digest the food we eat in order to 
facilitate absorption of nutrients that can be used in various processes in our 
body. The digestive process includes mechanical and chemical breakdown, 
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and absorption. This process starts before eating; just thinking of, tasting, 
smelling, chewing and swallowing food, stimulate production of gastric acid 
in the stomach. Then the food is chewed into smaller pieces in the mouth and 
is mixed with enzymes. The process continues in the stomach where the food 
is mixed with gastric acid and even more enzymes. Some digestion of 
carbohydrates and proteins takes place in the stomach; however, the final 
breakdown occurs in the small intestine.  
When gastric acid enters the first part of the small intestine, i.e. the 
duodenum, the endocrine cells are triggered to neutralize the acidic intestinal 
content (chyme) in order to optimize the chemical effect from pancreatic 
digestive enzymes and bile, and also to protect the small intestine from the 
gastric acid. At the same time as the chyme is digested, it is transported 
through the GI tract in a suitable pace to make the nutrient absorption as 
effective as possible. The motility of the small intestine mixes and moves the 
content slowly forward towards the colon, until the majority of nutrients are 
absorbed. The intensity of the contractions is dependent on the 
parasympathetic and the sympathetic nervous system, the enteric nervous 
system and hormones. Under normal conditions, few unabsorbed nutrients 
are left when the chyme enters the colon. There are however a huge quantity 
of bacteria in the colon that can synthesize vitamin K, and break down 
cellulose and unabsorbed carbohydrates through fermentation. The amount of 
bacteria varies and for example increases when the consumption of dietary 
fibers is large, and treatment with antibiotics decreases the bacterial number. 
Bacterial metabolism produces gases such as carbon dioxide, methane and 
hydrogen (39).  
Carbohydrates consist of starch, glycogen, cellulose, and different 
saccharides. Carbohydrates must be digested into monosaccharides in order 
to be absorbed and this is done by different enzymes secreted from the 
salivary glands, stomach, pancreas, and from epithelial cells in the small 
intestinal brush border. The monosaccharides glucose and galactose are 
effectively absorbed in the small intestine into the portal vein, but the 
capacity to absorb fructose, another monosaccharide, is limited and 
dependent on the concurrent absorption of glucose. Excess fructose and other 
non-digested carbohydrates are transported to the colon, where they are 
fermented into short chain fatty acids that generally are considered to be 
beneficial to health (40). Fructose and also sorbitol are incompletely absorbed 
in the normal small intestine, and simultaneous ingestion of glucose enhances 
fructose absorption and malabsorption occurs only when fructose is present 
in excess of glucose (41).  
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Proteins are digested by the enzyme pepsin to peptides in the stomach, and 
the major breakdown takes place in the small intestine by different proteases 
in the pancreatic juice. The end products are short-chain peptides and amino 
acids, and the epithelial cells absorb both smaller peptides and amino acids to 
the portal vein. 
Lipids (fats) consist mainly of triglycerides. The digestion of lipids occurs 
exclusively in the small intestine due to the necessary addition of pancreatic 
lipase and bile. The end products after fat digestion are free fatty acids and 
mono-glycerides. 
Absorption of water is very efficient in the intestine. When different 
substances are absorbed, water follows, through osmosis. The small intestine 
and the colon absorb approximately 99 % of the water. 
Only a small part of the feces, from a normal diet, are undigested food, and 
feces consist mainly of waste products, rejected epithelial cells and colon 
bacteria. 
 
 
Accurately measuring diet in free-living human subjects is difficult to 
accomplish with precision. The appropriate tool for dietary assessment will 
depend on the purpose for which it is needed. Different methods have been 
developed for the purpose of assessing dietary intake. These range from 
simple food lists, household survey methods, food frequency questionnaires 
to detailed individual weighed records collected over a period of several 
days. Each method has its merits, practical difficulties and associated errors 
that needs to be considered (42). The purpose for which the dietary 
assessment is needed will decide the appropriate method. The purpose may 
be to measure nutrients, foods or eating habits on individual levels or in a 
larger group of subjects. In Table 2 an overview of the most common self-
report dietary assessment methods are presented. When validating dietary 
assessment methods, i.e. biomarker-based validation, underreporting is most 
often observed. Recall methods are limited by memory. Record methods are 
biased by the fact that the subjects are likely to change their intake and both 
methods are potentially affected by over-reporting of healthy foods or what 
the subject ????????????????????? 
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Table 2. Overview of common self-report dietary assessment methods. 
Method Description Strengths Weakness 
Weighed food 
record 
(commonly 3-7 
days; 7 days is 
“gold 
standard”) 
The subject weighing 
every item of food and 
drink prior to consumption 
in a specially designed 
booklet. 
Widely used methods 
Precision of portion sizes 
High respondent burden 
Misreporting              
Changing intake behavior   
Day-to-day variations     
Coding requires expertise 
Estimated food 
record 
The subjects register every 
item of food and drink 
prior to consumption in a 
specially designed booklet. 
The portion size is 
estimated or household 
measures are used. 
Widely used method 
Lower respondent burden 
than weighed food diaries 
Relatively high respondent 
burden  
Estimation of portion size 
Misreporting                   
Day-to-day variations   
Coding requires expertise 
24-h recall 
A trained interviewer asks 
the respondent to 
remember in detail all the 
food and drink they 
consumed during the 
previous 24 hours. 
Low respondent burden 
Can be administered by 
telephone 
Requires a trained 
interviewer                    
Relies on memory       
Estimation of portion size 
Single day vs day-to-day 
variation                      
Coding requires expertise 
Diet history 
A trained interviewer asks 
the respondent to describe 
customary food and/or 
nutrient intakes over a 
relatively long period e.g. 
6 months or longer. 
Low respondent burden 
Can be administered by 
telephone 
Cannot be self-completed 
Relies on memory        
Estimation of portion size 
Coding requires expertise 
Food 
Frequency 
Questionnaire 
Consists of a list of foods 
and a selection of options 
relating to the frequency of 
consumption (i.e. times a 
day/daily/weekly/monthly) 
Low respondent burden 
Can be self-completed 
Can be optically scanned 
Estimation of portion size 
Possible over-reporting of 
“healthy” foods 
 
 
Traditionally, the diet-record method has been considered to be the most 
accurate method to assess food intake. However, the validity depends on the 
subjects’ willingness to cooperate. The number of consecutive days of 
recording often influences the compliance, the recording can interfere with 
normal eating behavior, and the subjects may alter their intake due to self-
consciousness, being ashamed or convenience (43). The estimated method to 
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assess nutrient intake is widely used, with a lower burden on respondents 
than the weighed food diaries. The weakness of this method is however 
difficulties when the investigator converts these estimates into weights that 
can then be used to calculate food and nutrient intake, and it is of course 
more time consuming for the investigator.  
 
Alternative methods have other limitations, for instance underreporting due 
to limits of memory (diet history, 24-h recall method). Food-frequency 
questionnaires (FFQs) are designed to collect dietary information from large 
numbers of individuals. Depending on the length of the food list, and if 
portion size is not included in the questionnaire, it is not possible to measure 
the complete nutrient intake from these questionnaires. Validation of these 
self-reported dietary intake approaches, through methods with biomarkers, 
has unfortunately shown underreporting and systematic and random errors 
(44). However, only a few biomarkers (e.g. energy and protein) qualify as 
valid reference instruments to reflect dietary components (44). When 
performing studies to assess nutrient intake in a population, one has to take 
above-mentioned limitations into account and weigh these against the 
purpose of the investigation. 
 
 
Food and diet concerns patients with IBS (45), and they frequently report 
association between food ingestion and onset or worsening of GI symptoms 
(46, 47). The majority of IBS patients report adverse reactions to one or more 
foods and consider that their symptoms are aggravated by food intake. 
Several studies have investigated this and have come up with more or less the 
same findings, i.e. approximately two thirds of IBS patients report an 
association between food intake and worsening of their symptoms (46-49). In 
one study, female sex and anxiety seemed to predict a higher degree of food-
related symptoms in IBS patients (46), which is in line with the finding that 
female IBS patients report more changes in their dietary habits because of GI 
problems than men with IBS (47). 
Many IBS patients believe that food allergy or specific food intolerances can 
explain their symptoms (47). Food allergy is an immune response that occurs 
reproducibly on exposure to a specific food and can result in different 
symptom manifestations, including anaphylactic shock, which is a very 
severe condition. Food allergy is found in about 2-10 % of the general 
population (50), but there is no evidence to date that has suggested an 
increased frequency of food allergy in IBS compared to the general 
Food-related gastrointestinal symptoms, nutrient intake and dietary interventions in patients 
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population (51-53), even though there may be a subgroup within the IBS 
population where a link to genuine allergy mechanisms may be involved in 
symptom generation (54). However, perceived food intolerance, on the other 
hand, which is very common in the general population (55), is even more 
common in IBS, as 20-65 % of IBS patients attribute their symptoms to these 
non-toxic and non-immune-mediated adverse reactions to food (46, 47, 56, 
57), but the underlying mechanisms are not well understood. Psychological 
factors are common in patients with symptoms compatible with IBS who 
attribute their symptoms to food intolerance (46, 58), but still only explains a 
small proportion of the variance in symptom severity in patients with self-
reported food intolerance (59), so this does not seem be the major 
explanatory factor for food intolerance in IBS.  
Typical symptom generating foods in patients with IBS are foods rich in fat 
(60) and carbohydrates (61-64), as well as cabbage, onion, beans, milk, 
wheat, coffee, peas/beans, hot spices, deep-fried food, pizza and cream (46, 
47, 65). The current opinion is that a more general food sensitivity is a 
plausible explanation to some of these reactions, and the potential underlying 
mechanisms are discussed below. The perceived food intolerance may lead to 
avoidance of different foods in IBS, and sometimes patients risk nutrient 
deficiency. Several studies report that people with IBS often avoid different 
food items as a way of coping with the disease, which possibly could lead to 
a lower intake of essential nutrients (2, 46, 47, 66, 67). However, patients 
with IBS seem to have a body mass index (BMI) comparable to the general 
population (46), and few studies have addressed nutrient intake in IBS and 
assessed the nutritional adequacy of their diet (68). Moreover, differences in 
the presence and severity of subjective food intolerance between subgroups 
of IBS patients are not well covered in the literature.  
When comparing individuals with IBS with subjects without IBS, there is 
weak evidence suggesting increased incidence of lactose malabsorption in 
IBS patients, when using a hydrogen breath test (69-72). The importance of 
lactose intolerance in IBS is therefore questionable, but in some studies 
lactose intolerance has been reported to be of relevance for patients with IBS, 
and a positive effect on symptoms after lactose restriction has been 
demonstrated (69, 71, 73). However, there are also other studies with limited 
or no effect of lactose restriction in IBS patients (70), so the clinical 
relevance of lactose intolerance is still controversial. 
Failure to completely absorb fructose in the small intestine, i.e. fructose 
malabsorption, is common in the general population, and is usually not linked 
to symptoms (74). However, in IBS patients it has been proposed that the 
Lena Böhn 
9 
presence of fructose malabsorption may be of relevance for symptom 
generation, even though it is probably not more common with fructose 
malabsorption in IBS patients than in the general population (62, 75), but also 
this is controversial, as opposing studies exist (76).  
 
 
 
Fat is an important mediator of postprandial GI motor and sensory effects 
(77) and a potent stimulating factor of the colonic response to a meal (78). It 
is well known that especially large meals and meals with a high fat content 
are potent stimulators of the gastrocolonic response in general (79, 80), and 
in IBS patients in particular (81). Moreover, also in the upper part of GI tract, 
fat has profound effects on GI physiology, including effects on various GI 
peptides, with both GI and non-GI effects (82), which may also be involved 
in symptom generation after intake of fatty foods in IBS patients.  
Abdominal pain after a meal is a common feature in IBS patients. One 
potential explanation behind this is the fact that the colonic hypersensitivity, 
seen in many IBS patients, is exaggerated after delivery of fat into the 
proximal small intestine. This has been studied by measuring the sensitivity 
to balloon distensions in the sigmoid colon before and after administration of 
lipids into the duodenum. A larger proportion of patients reported pain at the 
different pressure steps during the balloon distension after versus before 
duodenal lipids, and this was different from the findings in healthy controls, 
supporting an exaggerated sensory component of the gastrocolonic response 
in IBS patients (60, 83). It is tempting to speculate that this mechanism is 
involved in postprandial symptoms in IBS. 
 
Another potential mechanism behind worsening of symptoms in IBS patients 
after meal intake is the effect of nutrients on gas transit and tolerance. 
Bloating and abdominal distension are prominent symptoms in patients with 
IBS and other functional GI symptoms, and it has been demonstrated that 
IBS patients with abdominal bloating have disturbed gas transit in the GI 
tract and tend to accumulate gas in the GI tract and also have a reduced 
tolerance to gas in the GI tract (84). This is modulated by nutrients, and 
especially the effect from lipids on gas transit and tolerance is enhanced in 
patients with IBS (85).  
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Taken together, lipids may worsen symptoms in IBS through different 
mechanisms, and probably the relative importance of these may differ 
between individuals. 
 
 
As stated above, many patients with IBS report symptoms after intake of 
food items rich in different carbohydrates, and this may be related to 
incomplete absorption of different carbohydrates in the small intestine 
leading to negative effects in the colon in sensitive individuals. Traditionally, 
IBS patients have been encouraged to increase intake of dietary fibers (86), 
but many IBS patients state that their symptoms are worsened by increased 
fiber intake (87). Dietary fibers are non-starch polysaccharides that are 
mainly found in plant cell walls, and includes insoluble fibers (e.g. lignin, 
celluloses, and some hemicelluloses), and soluble fibers (e.g. ?-glucan from 
oats and barley, pectin and gums in psyllium) and these have well established 
positive effects on health in general (88). In functional GI disorders, the 
positive effect of dietary fibers on stool form/consistency has been used 
therapeutically (89) but there is still conflicting data whether increasing or 
decreasing intake of dietary fibers is beneficial in subjects with IBS (87, 90, 
91).  
Many of the food items that are rich in dietary fibers, such as cereals, 
wholemeal bread, vegetables and fruits, also contain large amounts of 
incompletely absorbed short-chain carbohydrates which may cause GI 
symptoms in individuals with IBS through fermentation and osmotic effects 
in the colon when ingested (61). In fact, in the last years several lines of 
evidence have emerged showing that intake of food rich in these 
incompletely absorbed short-chain carbohydrates, collectively called 
FODMAPs - Fermentable Oligosaccharides, Disaccharides, Monosaccharides 
And Polyols - can be responsible for symptoms in large groups of patients 
with IBS (92). In line with this, recent evidence has suggested that reducing 
the FODMAPs content is efficient in reducing symptoms in IBS and other GI 
conditions (64, 93-97). In the FODMAPs concept the following groups of 
carbohydrates are included: 
? Oligosaccharides: The human GI tract lack enzymes that are 
able to hydrolyze certain oligosaccharides, such fructans and 
galacto-oligosaccharides (GOS), thus absorption of these are 
not possible (98). Foods that contain large amounts of 
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oligosaccharides are peach, artichoke, wheat, rye, onion, 
legumes, chickpeas, lentils.  
 Disaccharides: The dietary disaccharides, sucrose, lactose, 
maltose, isomaltose and trehalose are hydrolyzed by 
enzymes (disaccharidases) expressed by small intestinal 
epithelial cells. The absorption of lactose relies on the 
activity of the enzyme lactase in the epithelial brush border. 
Of the disaccharides this is the only enzyme that is 
commonly deficient, as lactase deficiency is the common 
state in the main part of the world, leading to unabsorbed 
lactose passing into the colon. However it varies greatly in 
different ethnic groups, with the frequency of maintained 
lactase production being larger in northern Europeans than 
in Asian and African ethnic groups (99, 100). Typical foods 
containing lactose are milk, yoghurt, and ice-cream.  
 Monosaccharides: The absorption of dietary mono-
saccharides varies. Glucose and galactose are effectively 
absorbed in the small intestine. However, the absorption of 
fructose is more variable, and is dependent on the concurrent 
presence of glucose (101). When fructose is present in 
excess of glucose, malabsorption occurs, as co-ingestion of 
glucose enhances fructose absorption (41). Some fruits and 
vegetables contain large amounts of “free” fructose, for 
example apple, cherries, watermelon, asparagus, artichokes, 
and honey, and ingestion of large amounts of such food 
items may therefore lead to substantial amounts of fructose 
passing unabsorbed to the colon.  
 Polyols: The ability to absorb polyols (sorbitol, mannitol, 
maltitol and xylitol) varies between individuals and across 
different polyols, and the absorption is generally slow and 
passive. Polyols are present in foods such as apple, apricot, 
cauliflower, and in all sugar substitutes that end with  –ol 
(e.g. sorbitol, maltitol, xylitol). 
The mechanisms through which FODMAPs may cause symptoms in 
susceptible individuals are through osmosis and fermentation. Short-chain 
carbohydrates are osmotically active and if they are incompletely digested or 
absorbed, or if the absorption process is slow, this will increase the water 
volume in the small intestine. They can also be fermented in the colon, 
leading to production of different gases. These two actions will lead to 
luminal distension that may aggravate symptoms in subjects with IBS (92, 
102, 103). The increased luminal water may in addition to distension also 
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lead to looser stools. Moreover, besides gases, the colon bacteria also 
produce osmotically active short-chain fatty acids with effects on sodium and 
water absorption, as well as on motility. However, not all subjects that ingest 
large amounts of FODMAPs report symptoms (76) and the presence of 
visceral hypersensitivity or other factors may be an additional prerequisite to 
have symptoms after FODMAPs ingestion (92, 93). 
Based on these findings, a diet with low FODMAPs content has been tested 
in IBS with promising results, i.e. marked improvement of GI symptoms 
results in the majority of patients (94-96). The low FODMAPs diet implies a 
carbohydrate restricted diet, and the potential problem is that it is quite 
intrusive and difficult to follow, and the long-term effects are still not known, 
with potential negative effects on gut microbiota composition (97, 104).  
 
 
Gluten has recently been put forward as an important dietary factor to 
consider in patients with IBS, even in the absence of celiac disease (105). The 
mechanism behind the potential negative effects of gluten in IBS is still 
debated, but effects on intestinal permeability (106), a FODMAPs effect 
(107) or immune mechanisms (108) are plausible. Other dietary factors that 
may affect GI function negatively in IBS patients include alcohol and 
caffeine (46, 47).  
Recently, alterations in gut microbiota composition and function have been 
put forward as an important factor in functional bowel disorders (27).The GI 
microbiota is the microbe population living in our intestine. It contains tens 
of trillions of microorganisms, including at least 1000 different species of 
known bacteria. Microbiota can, in total, weigh up to 2 kg. One third of our 
GI microbiota is common to most people, while two thirds are individually 
unique (109). Diet profoundly affects gut microbiota and many of the effects 
of the diet on gut function can be modified by the gut microbiota composition 
and function (110). Therefore, manipulation of gut microbiota through 
dietary changes has been put forward as one promising treatment option for 
IBS in the future. Moreover, part of the variance in response to different 
dietary manipulations may be due to differences in gut microbiota 
composition.  
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Diet and lifestyle changes are important management strategies in IBS. 
However, few randomized controlled trials exist on dietary treatment of IBS 
patients. Instead, the current recommendations are primarily based on studies 
assessing physiological function in relation to dietary components (57, 111). 
In 2012, the British Dietary Association published evidence-based guidelines 
for the dietary management of IBS in adults (112), even though these were 
mainly based on non-randomized trials. A comprehensive literature search 
was conducted and relevant studies from 1985 to 2009 were identified and 
critically appraised. Three lines of dietary management were identified where 
the first line includes clinical and dietary assessment and advice about 
healthy eating and lifestyle management, including physical activity and also 
some general advice on lactose and non-starch polysaccharides. In the second 
line there were more advanced dietary interventions to reduce IBS symptoms, 
which include non-starch polysaccharides, FODMAP and also 
recommendations about probiotics. The third line included elimination diets. 
In the conclusion the authors raised the need for adequately powered 
randomized controlled trials on different dietetic strategies in the future. 
Some of the currently used approaches to dietary advice in IBS are briefly 
discussed below.  
 
 
An increase of dietary fibers has been widely advocated as a first-line 
treatment in IBS, based on the effect on stool form and consistency, but with 
contradictory results. This advice was based on positive initial results of a 
diet with high wheat-fiber content on IBS symptoms (86). However, several 
studies failed to confirm these positive results (113, 114), and a survey of 
IBS patients later found that 55 % of the patients even reported a 
deterioration by bran, whereas only 10 % found it helpful (87). These 
disappointing results of an increased fiber intake in IBS patients may be 
related to an abnormal colonic fermentation (115). Today the advice 
regarding increasing fiber intake is mainly proposed to patients with 
constipation as their main complaint, and to use soluble fibers, particularly 
ispaghula or psyllium, instead of the insoluble fiber wheat bran (116). 
Soluble fibers, which is prevalent in several fruits, such as apricots, figs and 
prunes, have a greater water-holding capacity than insoluble fibers and a 
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more pronounced effect on fecal bulking, which is probably beneficial for 
IBS patients.  
A majority of patients with lactose intolerance can consume a considerable 
amount of lactose before having symptoms (117), and the use of enzymatic 
treatment (lactase supplements) seems to be of limited value (118). 
Therefore, perceived lactose intolerance could be relevant only for a 
subgroup of IBS patients. In these patients a lactose reduced diet might have 
a positive effect on some of the symptoms, especially diarrhea and 
gas/bloating, but the general impression is that the importance of lactose 
intolerance in IBS have been overestimated during the past.  
Up to 96 % of individuals with IBS state that abdominal bloating occurs 
(119), and is the most bothersome symptom in a large proportion of the 
patients (120). Abdominal bloating increases in severity during the day, when 
eating and then settles overnight (119, 120). There is good evidence that 
intake of fermentable carbohydrates, FODMAPs, could increase the severity 
of bloating, but also loose stools in IBS subjects (121, 122). Avoidance of 
FODMAPs is therefore recommended in order to reduce symptom severity of 
bloating and other GI symptoms observed, and this recommendation is based 
on controlled clinical trials (123). However, available treatment trials have 
either used a standard or habitual diet as comparator, without the aim to 
improve symptoms with this comparative diet (96, 97), or used a non-
randomized, non-blinded study design (64). This dietary regime requires 
specialist dietetic knowledge for successful compliance and detailed 
information on which food to avoid. The first 2-8 weeks the diet is proposed 
to be as strict as possible in order to achieve symptom relief, and thereafter a 
planned and systematic re-introduction of foods high in fermentable 
carbohydrates is recommended (64). In order to have an adequate dietary 
regime in the long run, it is considered essential to reintroduce foods 
containing FODMAPs to identify the carbohydrates that are tolerable on an 
individual basis and those that trigger symptoms. The reintroduction should 
include one FODMAP at a time during three days. If no symptoms occur 
with e.g. honey (fructose), a challenge with the next FODMAP during three 
days can be pursued. The method demands perseverance and careful planning 
together with a dedicated and well-informed supervisor, and so far no clinical 
trials demonstrating that this approach with reintroduction is effective and 
how this should be done exist. All clinical trials assessing the effect of low 
FODMAPs diet in IBS are 2-4 weeks. Moreover, FODMAPs, as well as 
resistant starch, are suggested to have positive physiological effects on 
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colonic health, which may lower disease risk just like prebiotics (124). 
Recent studies have shown that low FODMAPs diets have led to alterations 
in colonic luminal microenvironment (104, 125), which potentially may have 
negative health effects long-term, but this needs to be addressed in 
prospective follow-up studies. Therefore, health implications and functional 
significance of reduced intake of fermentable carbohydrates might lead to 
caution about reducing the intake of FODMAPs in the long term and the 
restriction of such carbohydrates only to the level of adequate symptom 
control is recommended. 
One interesting approach that would reduce the need to follow a strict 
carbohydrate restricted diet in order to improve symptoms would be to 
administer an enzyme that could digest poorly digested carbohydrates, and 
thereby facilitate absorption in the small intestine. This approach is currently 
used for lactase deficiency, where lactase can be administered (100). ?-
galactosidase is an enzyme with amylase-like activity, which has been 
reported to be effective in reducing gas production and relieving gas-related 
symptoms after meals rich in incompletely absorbed carbohydrates (126-
128). The enzyme is derived from the mold Aspergillus niger and can break 
down fructans and GOS in the small intestine before they are metabolized by 
colonic bacteria. By this mechanism ?-galactosidase has the potential to 
facilitate the intestinal absorption and to minimize the bacterial gas 
production of these carbohydrates. This enzyme has been tested in healthy 
subjects and in children with IBS, with a reported reduction in GI symptoms, 
particularly gas-related complaints, when ingested in conjunction with meals 
(126-129). However, it is not yet established if ?-galactosidase is efficient in 
alleviating GI symptoms in adult patients suffering from IBS. 
 
 
The gut microflora can be an important part in the pathophysiology of IBS 
and a modulation of this environment may improve symptoms (130). There is 
emerging but conflicting evidence for the use of probiotics in IBS (131). 
Even though the overall effect is modest and probiotics are unlikely to be 
beneficial for all IBS patients, it seems as some probiotics are favorable in 
improving symptoms. However, the preferred probiotic strains, products, and 
regimen of use are not clear (132, 133). 
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Most patients with IBS have made alterations in their diets, which in some 
cases may be extreme. Food elimination diets have been used to identify food 
intolerance or allergy in individuals with IBS. However there are no standard 
diet describing which foods should be excluded, and this diet should only be 
tried when single food avoidance has not improved symptoms and when 
multiple food intolerance are suspected (111). Food elimination diets are time 
consuming for the patient and for the practitioner, as it usually take 3-4 
months to complete, including re-introduction phase. The elimination diet 
requires a high degree of motivation and compliance (65, 134). Potentially 
offending foods can only be identified after elimination and subsequent 
reintroduction. A detailed review is required after completion of the 
elimination diet and food reintroduction phase to assess the nutritional 
adequacy of the diet. However, existing studies with elimination studies in 
IBS show conflicting results (65, 111, 135-138), and in current 
recommendations and narrative reviews on dietary advice in IBS, extensive 
elimination diets are not recommended (4, 57).  
There is one study that have used a food elimination diet based on IgG 
antibodies to various foods in IBS patients with good results (134), but no 
study has reproduced these findings, and another study found no association 
between IgG to various foods and symptoms (139), so this approach is still 
controversial.  
 
 
Other common dietary advice often includes reducing the intake of coffee 
and fat, despite the fact that randomized controlled studies supporting this are 
lacking (57). This is instead based on studies assessing physiological function 
in relation to these dietary components (78, 140), and to a lesser degree upon 
research examining the role of dietary components in the therapeutic 
management of IBS patients. Moreover, eating small, frequent meals, rather 
than large, infrequent meals are often recommended, which is also based on 
GI physiologic effects of larger versus smaller meals (79, 80). Another 
approach that is gaining popularity is to reduce the gluten content in the food, 
but as stated above, the evidence supporting this dietary approach in patients 
without celiac disease is controversial (108).  
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The overall aim of this thesis was to acquire a better understanding of the 
nutrient intake in IBS patients and impact of food on IBS symptoms, in order 
to improve dietary advice given to patients suffering from this condition. 
To determine the nutrient intake in IBS patients in comparison with the 
general population, as well as evaluating if their nutrient intake meet nutrition 
recommendations. 
 
To determine which food groups and specific food items IBS patients report 
to cause GI symptoms, and to investigate the association with GI, 
extraintestinal and psychological symptoms, as well as with quality of life. 
 
To assess if the enzyme ?-galactosidase is superior to placebo in reducing GI 
symptoms and intestinal gas production after ingestion of carbohydrate-rich 
meals in adult patients with IBS. 
 
To compare the effects on IBS symptoms between a low FODMAPs diet and 
traditional dietary advice in patients with IBS.  
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Papers I-II. We included patients with IBS according to the Rome III (5) 
criteria, who participated in treatment trials and in a study assessing the 
relative importance of different pathophysiological factors in IBS at the 
gastroenterology outpatient clinic at Sahlgrenska University Hospital. The 
patients completed questionnaires as part of the baseline evaluation in these 
trials. We excluded patients with other severe diseases that were likely to 
have an impact on nutrient intake and GI symptoms.  
Paper III. IBS patients that previously had taken part in studies at the 
gastroenterology outpatient clinic at Sahlgrenska University Hospital were 
invited take part in this study. They were already diagnosed with IBS 
according to the Rome III criteria (5), and had specific complaints of frequent 
bloating, abdominal distension and/or flatulence determined by the Rome III 
Modular questionnaire (141) and the distension/bloating sub-score of the IBS 
Severity Scoring System (IBS-SSS) questionnaire (142).  
Paper IV. We recruited IBS patients meeting the Rome III criteria (5) from 
the gastroenterology outpatient clinics at Sahlgrenska University hospital in 
Gothenburg, Karolinska University Hospital and Sabbatsbergs Hospital in 
Stockholm. In Gothenburg the patients were also recruited through 
advertisement in the local newspaper. We excluded patients with other severe 
diseases that were likely to have an impact on symptom generation, and also 
patients that already followed a diet excessively restricting certain nutrients.  
 
All patients completed questionnaires at different stages of the studies as 
specified below. 
In Papers I-IV the patients completed the IBS-SSS (Figure 1). This 
questionnaire assesses the severity of IBS symptoms during the previous ten 
days. The score ranges from 0 to 500. ?????????????-?????????????????????????
were divided into three groups; < 175 mild IBS; 175 ? 300 moderate IBS; 
and > 300 severe IBS (142). 
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Figure 1. Schematic figure demonstrating the included items in IBS-SSS. 
 
 
Moreover, in Paper III, a modified version of the IBS-SSS was completed in 
the morning, the day after each test day, in order to specifically assess the 
effects of the study medication. The modified questionnaire version included 
only the current experience of severity of abdominal pain, abdominal 
distension and dissatisfaction with bowel habits.  
In Paper IV the patients recorded all bowel movements in a stool diary, based 
on BSF, the Bristol Stool Form scale (5), every day during the screening 
period, as well as during the intervention period. The stool frequency was 
recorded as number of stools per day and the BSF scale was used to assess 
the mean stool consistency. Information from the stool diaries were used to 
subtype IBS patients according to Rome III, (5), and to assess changes in 
stool frequency or consistency during the intervention period compared to 
baseline. This form had also been used in Paper I-II to subtype patients. 
 
In Paper III, the severity of eight GI symptoms were rated (scores from 0 to 
20) in a symptom-questionnaire; gas, bloating, abdominal discomfort, 
abdominal distension, nausea, stomach rumbling, urgency to have a bowel 
movement and abdominal pain. This questionnaire was completed each half-
hour during test days (143).  
 
 
IBS Symptom Severity Score         
(IBS-SSS) 
Abdominal 
pain 
intensity 
Life 
interference 
Dis-
satisfaction 
with bowel 
habit 
Abdominal 
distension 
Abdominal 
pain 
frequency 
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In Papers I and II patients completed the Hospital Anxiety and Depression 
(HAD) scale to assess severity of general anxiety and depression, 
respectively (144). For the analyses in Paper I we used the HAD scale cut-off 
scores to define patients with and without clinically significant anxiety and 
depression ????????????. 
 
In Papers II and IV, the Visceral Sensitivity Index (VSI) was used to measure 
GI symptom-specific anxiety (22, 145). Higher scores on both of these scales 
assessing general and GI-specific anxiety, and depression, indicate more 
severe symptoms. 
In Paper IV, the Multidimensional Fatigue Inventory-20 (MFI-20) (146) was 
used to assess the severity of general fatigue, physical fatigue, reduced 
activity, reduced motivation and mental fatigue. A higher score indicates 
more severe fatigue.  
 
The Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL) was 
used in Paper II to measure effects of IBS symptoms on quality of life, 
divided into nine dimensions (147). A low score implies poor quality of life.  
 
The patients in Paper II completed a questionnaire assessing the occurrence 
of symptoms from intake of 56 different food items or food groups, without 
any severity grading. This questionnaire is frequently used clinically at the 
department of allergology at Sahlgrenska university hospital as an assessment 
tool of food intolerance. The included food items or food groups were chosen 
to include relevant foods implicated in food allergy and intolerance (53, 148-
150). The foods were grouped according to different potential underlying 
mechanisms/content responsible for symptom generation, such as foods 
containing incompletely absorbed carbohydrates, fat, biogenic amines, 
lectins, preservatives or having a potential to release histamine or to cross-
react with airborne allergens (Figure 2). Only food items reported to cause GI 
symptoms were included in the analyses (Paper II). The results were used to 
assess the proportion of subjects reporting GI symptoms as well as the 
number of food items reported to cause GI symptoms in each individual as a 
measure of the degree of self-reported food intolerance.  
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Figure 2. Foods in the self-reported questionnaire responsible for symptom 
generation. 
 
 
Papers I and IV. The IBS subjects were given thorough instructions from a 
dietitian in order to accurately complete a food record. The dietary intake 
data was obtained for four days; 3 consecutive weekdays and one connected 
weekend day (Paper I) or Wednesday-Saturday (Paper IV). Patients were 
instructed to consume their usual diet, to enter time of the food intake, the 
specific food item, and to enter the amount in the food diary as accurately as 
possible (in grams or household measures). All food items and beverages 
were entered in the software Dietist.XP version 3.1 (Kostdata.se, Stockholm, 
Sweden), which converts food items into nutrients and energy amounts. 
 
 
 
Benzoic 
acid 
 
 
 
 
 
Sour milk/yoghurt 
Orange 
Lingonberry 
Amines 
 
 
 
 
 
 
Cheese 
Fish 
Wine/beer 
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Cayenne/red pepper 
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Bell pepper 
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Soy 
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Composite foods were split into ingredients. From the 4-days food records, 
average daily intakes were calculated.  
In Paper IV, a new Swedish database was used in addition to Dietist.XP, to 
assess the content of lactose, fructose, galacto-oligosaccharides, fructans and 
polyols (Liljebo et al. Manuscript in preparation). 
 
Paper I. To assess the nutritional intake of the general population we used 
data from a national dietary survey, ???????????? conducted in 1997-1998, 
where the participants had completed a pre-coded food diary with pre-printed 
alternatives for food items, and meal components. They had access to a 
portion-guide with food photographs to estimate amounts of food, together 
with amounts in household measures, pieces, etc. Analysis of the data from 
the food registration of the national dietary survey was performed using the 
software MATs, version 4.03 (Rudans Lättdata, Västerås, Sweden), which 
covers around 1700 foods and 48 nutrients. 
 
 
Paper III. The breath test is a non-invasive test that can detect hydrogen and 
methane gas produced by bacterial fermentation of unabsorbed carbohydrates 
that is excreted in the breath. Hydrogen is derived only from bacterial 
metabolism in the intestine, and methane is produced through consumption of 
hydrogen by methane-producing bacteria, methanogens (151, 152). 
 
Samples of expired air were collected each half-hour during test days to 
assess the concentrations of hydrogen and methane in parts per million 
(ppm). All breath samples were end-expiratory and collected in a system used 
for the sampling and storing of alveolar air (GaSampler System, QuinTron 
Instrument Company, Milwaukee, WI, USA). Analysis was immediately 
done by use of a gas chromatograph (QuinTron Breath Tracker, QuinTron 
Instrument Company, Milwaukee, WI, USA).  
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Paper III. The participants arrived in the morning the test day and completed 
questionnaires. The patients were randomized to receive three capsules 
containing the digestive enzyme ?-galactosidase (Nogasin®, Oy Verman, 
Kerava, Finland) or a corresponding placebo with identical capsule design 
before start of three study specific meals at both of the study days. Each 
capsule with the active enzyme had a total content of 400 galactosidic units 
(GaUI) where 1 GaUI equals the amount of enzyme that releases 1 µmol of 
galactose from the substrate in 1 min. The dose of the enzyme given at each 
meal during the active treatment day by consequence was 1200 GaUI. They 
were served a carbohydrate-rich breakfast and lunch together with enzyme or 
placebo (Table 3, Figures 3 and 4). Symptom registration (the meal-related 
GI symptoms questionnaire, see above) and breath samples were collected 
every half hour for 7.5 hour in all participants. In the evening at home the 
patients were instructed to eat a prefabricated dinner meal. Two weeks later 
the procedure was repeated, however, the content of the capsules was the 
opposite from the first visit. The patients completed the IBS-SSS 
questionnaire before breakfast each test day and also the modified IBS-SSS 
the morning after test day (before breakfast).  
 
Table 3. The composition of the test meals.  
Time  Food Nutrients 
Breakfast 
8.00 
Rye porridge, jam, lactose free- milk  
Wholemeal bread, margarine, cheese, bell pepper 
Apple juice 
736 kcal 
15.2 g protein 
18.0 g fat 
108.3 g carbohydrates 
Lunch 
 
11.30 
Chicken and bean casserole 
(contents; beans, chickpeas, onion, garlic, tomato, chili, 
mushrooms, rape oil, black pepper, salt, stock cube, thyme) 
White bread (wheat), margarine, cheese  
Apple juice 
697 kcal 
52.0 g protein 
19.1 g fat 
73.0 g carbohydrates 
Supper  Fish au gratin (prefabricated) 
Apple juice 
780 kcal 
50.1 g protein 
22.5 g fat 
90.1 g carbohydrates 
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Figure 3. Rye porridge breakfast. 
 
 
Figure 4. Bean- and chicken casserole lunch. White bread (wheat), 
margarine, cheese and apple juice are missing in the picture. 
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Paper IV. Patients with IBS were randomized to receive dietary advice from a 
dietitian about one of two different diets: a low FODMAPs diet or traditional 
IBS dietary advice and to follow these diets for four weeks (Tables 4 and 5). 
The subjects were provided with both verbal and written instructions in the 
form of a pamphlet with detailed information of which foods to avoid and of 
alternative food items that could be ingested instead. The patients were 
blinded to the identity of the dietary advice (called “diet A” and diet B”, 
respectively). Symptom severity was assessed using the IBS-SSS and patients 
completed a 4-days food diary during screening and during the last week of 
the intervention period. A responder to the intervention was defined as a 
patient who demonstrated a reduction of the total score of the questionnaire 
IBS-SSS ≥ 50 at the end of the treatment period (day 29) compared with 
baseline (day 0).  
 
Table 4. A selection of instructions from the low-FODMAP diet (“Diet A”). 
Food to avoid  Suitable foods 
High in fructans and/or GOS   
Cereal grains (wheat, rye, barley) Rice, potato, oats, polenta, quinoa, buckwheat 
Bread and pasta (white, wholemeal) Wheat free or gluten-free bread and pasta 
Beans and pulses Green beans 
Garlic and onions Spring onion (green part), herbs 
Nuts and seeds; cashew, pistachios Peanuts, pecans, walnuts, sunflower seeds 
  
High in polyols  
Apple*, pear*, nectarine, plum, prune Banana, orange, kiwi, honeydew melon 
Cauliflower, mushroom, sweet corn Carrot, parsnip, cucumber, spinach, lettuce 
Sugar-free products with sorbitol, xylitol, 
mannitol 
Sugar, glucose syrup, dextrose 
  
High in fructose  
Mango, apple*, pear*, watermelon, honey Pineapple, strawberries, blueberry 
  
High in lactose  
Milk, yoghurt, ice cream Lactose free milk, yoghurt, ice cream 
  
  
Food to limit   
Coffee, alcohol, carbonated drinks Non-caffeinated drinks, water, non-fizzy 
drinks 
  
*Some food items contain more than one type of FODMAP, i.e. apples and pears are rich in 
fructose as well as polyols. 
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Table 5. A summary of the traditional ???????????????????. 
 
 
Papers I-II were retrospective studies which partially are based on the same 
study population (Table 6).      
? In Paper I we assessed the nutrient intake of IBS patients in 
order to investigate if they had a different intake compared 
to the general population. We also investigated if the intake 
differed between subgroups of IBS patients based on IBS 
severity, presence of absence of depression or anxiety, and 
the IBS subtype based on the predominant bowel habit. 
   
? In Paper II we evaluated the I??? ?????????? ????-reported 
symptoms from different food items and food groups. In 
relation to these reported food-related GI symptoms we 
investigated how levels of anxiety and depression, severity 
of IBS and somatic symptoms and quality of life influenced 
the perceived food intolerance, measured as the number of 
food items reported to cause GI symptoms. 
Papers III-IV were prospective studies (Table 6).  
? In Paper III we performed a randomized, double-blind, 
placebo-controlled, cross-over study to assess if ?-
galactosidase alleviates symptoms after intake of 
carbohydrate-rich meals. The patients were served two 
Dietary advice 
? Eat regular meals 
? Do not skip meals or eat late at night 
? Take your time when eating, chew your food well 
? Limit fatty foods, spicy foods, onions, legumes, coffee and alcohol 
? Avoid carbonated drinks, chewing gum and sugar-free products 
? If constipated: increase the amount of dietary fibers as well as fluids. 
? If diarrhea: limit intake of dietary fibers, berries are often better than fruits, cooked 
vegetables better than raw 
? Continue eating probiotics, however, do not start eating probiotics during the study 
period 
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meals at site and one meal was ingested at home, together 
with capsules containing α-galactosidase or placebo.  
 
 In Paper IV we performed a randomized, controlled, 
parallel, single-blind intervention trial where the participants 
were randomized to eat according to the low FODMAPs diet 
or to the traditional IBS dietary advice during four weeks. 
They completed several questionnaires during the screening 
period as well as during the intervention period to assess the 
effects of the dietary regimens on GI symptoms. 
Table 6. Design and methods for the included studies. 
 Paper I Paper II Paper III Paper IV 
Focus Food intake 
in IBS 
patients in 
comparison to 
general 
population 
Self-reported GI 
symptoms related 
to food intake 
Impact from 
enzyme 
supplementation 
on food related 
GI symptoms 
Effect of dietary 
advice on GI 
symptoms 
Design Retrospective 
Gender-age-
matched 
Comparative  
Case-control 
Observational 
 
Retrospective 
Cross-sectional 
Observational 
Prospective 
Randomized 
Double-blind 
Crossover 
Placebo-
controlled 
Interventional 
Prospective 
Randomized  
Single-blind 
Parallel 
Controlled 
Multi-center 
Interventional 
Data 
collection 
Cases were 
retrieved 
from two 
previous 
studies and 
one ongoing. 
Controls were 
retrieved 
from a 
national 
dietary 
survey. 
Participants in IBS 
studies aiming to 
explore 
pathophysiological 
factors in IBS.  
IBS patients 
with specific 
gas-related 
symptoms were 
recruited from 
previously 
performed 
studies. 
Subjects with 
IBS diagnosis 
were recruited 
from 3 Swedish 
gastroenterology 
units and through 
advertisement in 
local newspaper. 
Questionnaires IBS-SSS 
HAD 
Food Diary 
 
 
Self-reported food 
intolerance 
HAD 
VSI 
IBS-SSS 
PHQ-15 
IBSQOL 
IBS-SSS 
Modified IBS-
SSS  
Meal-related GI 
symptoms 
questionnaire. 
IBS-SSS 
BSF 
HAD 
VSI 
MFI-20 
PHQ-15 
Food Diary 
Food-related gastrointestinal symptoms, nutrient intake and dietary interventions in patients 
with irritable bowel syndrome 
28 
 
Papers I-IV. Descriptive data were presented as proportions for categorical 
variables and as mean values ± SD for the continuous ones, except for figures 
in Paper II, where box-and-whisker plots without extreme values and outliers 
were used.  
 
Papers I-II, IV. Differences in continuous variables between patients with 
IBS and the general population and between the two IBS severity groups 
were made using independent-samples ?????????? t-tests. The comparisons 
among the different IBS groups were performed using ANOVA and if group 
differences were detected, post hoc testing using Bonferroni correction was 
done. For correlation analyses between questionnaires in Paper II, Pearson?s 
product ? moment correlation coefficient was used.  
  
Paper III. Data were analyzed using linear mixed models implemented using 
the mixed procedure in SAS 9.4 software (SAS Institute, Cary, NC, USA). 
To test the response to the first two meals, the first 16 time points (up to 450 
minutes) were used. For the analysis, the first time point (0 minutes) served 
as the pre-meal baseline time point (reference category). Different models 
were estimated for each symptom as well as hydrogen and methane as the 
dependent variables. Drug and time were entered as categorical within-
subject independent variables. Main effects as well as the drug*time 
interaction effect were included in the model. The Kronecker product of an 
unstructured (drug) and first-order autoregressive (time) variance-covariance 
matrix was used to model the data as this provided the best fit based on the 
?????????????????????????????????????????????????????????????????????????????
of a differential symptom or breath test hydrogen response to the meal for 
active drug versus placebo, the drug*time interaction effect was followed by 
a planned contrast comparing the difference between the average of all post-
meal time points and the pre-meal baseline time point between active drug 
and placebo. Since this study was testing a hypothesis where the potential 
treatment effect was uncertain, no formal power calculation was done. 
Paper IV. The primary endpoint in this trial was the change in IBS-SSS at the 
end of the treatment period relative to baseline, and the proportion of 
responders to the dietary intervention based on the recommended cut-off of a 
reduction (=improvement) in IBS-???? ????? To plan our sample size, we 
performed a power calculation based on the ability to detect a difference 
between the two diets in reduction of IBS-SSS of at least 50 with 80 % power 
at ?=0.05, assuming a SD of 70, and this indicated that we would need at 
least 31 patients in each group. In order to have at least 62 evaluable patients, 
we planned to randomize at least 70 patients.  
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As secondary endpoints we analyzed the effect of the dietary interventions on 
the individual items of IBS-SSS, as well as on bowel habits measured by 
stool diaries. Moreover, the adherence to the dietary advice was assessed by 
comparing dietary intake at baseline with the last week of the intervention 
period within and between the treatment groups. Potential baseline predictors 
for being a responder (IBS-SSS reduction ≥50 at the end of the intervention 
period) were also evaluated by comparing baseline variables, i.e. 
questionnaire data, demographics, IBS characteristics and dietary intake 
between responders and non-responders in the treatment groups. Categorical 
variables were compared with chi-square test, whereas continuous variables 
were compared with independent -samples and paired -samples t-tests, after 
the normality of the distribution had been demonstrated with Kolmogorov-
Smirnoff statistic, and with histograms of the data. All patients who were 
randomized and who received dietary instructions were included in the 
responder comparisons, where drop-outs were considered to be non-
responders (intention to treat analysis), whereas for comparisons of 
questionnaire data at the end of the intervention period vs. baseline, only 
patients who completed the intervention are included (per protocol analysis). 
 
In all studies two tailed P-values less than 0.05 were considered statistically 
significant. Statistical analyses were performed using the SPSS statistical 
package, version 19.0 (SPSS Inc., Chicago, IL, USA), in all papers, except 
for Paper III. 
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Table 7 shows the baseline characteristics of the included participants in 
Papers I-IV.  
 
Table 7. Characteristics of the included participants in each paper. 
 
Paper 1 Paper II Paper III Paper IV 
 IBS 
patients 
n=187 
Controls 
n=374 
IBS 
patients 
n=197 
IBS 
patients 
n=20 
Low 
FODMAPs 
diet 
n=38 
Traditional 
IBS diet 
n=37 
Females, n 139 278 142 19 30 31 
Mean age, years 40 40 35 49 44 41 
Age range, years 19-70 19-70 18 ? 72 22-75 18-69 18-68 
       
Predominant bowel habit      
IBS-C, n 55 - 46 - 9 13 
IBS-D, n 62 - 86 - 10 8 
IBS-nonCnonD, n 70* - 65 - 19 16 
       
IBS-SSS        
Mild-moderate, n 94 - 79 3 15 18 
Severe, n 92 - 117 17 23 19 
       
HAD       
Anxiety, mean ± SD 6.4 ± 4.4 - 8.4 ± 4.5 8.0 ± 4.5 8.2 ± 4.5 7.0 ± 4.3 
Depression, mean ± SD 3.6 ± 3.6 - 5.1 ± 3.6 5.0 ± 3.8 5.1 ± 3.8 3.8 ± 2.9 
       
VSI, mean ± SD - - 47.0 ± 15.8 41.9 ± 16.3 40.6 ± 12.6 41.8 ± 16.7 
       
PHQ-15       
No/mild, n - - 56 5 10 12 
Moderate, n - - 76 9 18 13 
Severe, n - - 64 6 9 12 
       
IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; IBS-nonCnonD, IBS non constipation non diarrhea; 
IBS-SSS, IBS-Severity Scoring System; HAD, Hospital Anxiety and Depression scale; VSI, Visceral Sensitivity 
Index (GI-specific anxiety); PHQ-15, Patient Health Questionnaire-15 (Somatic Symptom Severity).  
* Subgrouping based on the predominant bowel habit missing in five patients in Paper I. 
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In this study we included 187 subjects with IBS according to the Rome III 
criteria and 374 age- and gender matched controls from a national dietary 
survey (153).  
The IBS patients reported higher intake of protein and dietary fibers than 
controls, but otherwise no significant differences in intake of energy and 
macronutrients were noted. The distribution of energy between protein, fat 
and alcohol were consistent with the Nordic Nutrient Recommendations 2004 
(NNR 2004) (154), but not for the carbohydrate and the dietary fiber intake, 
which were lower than recommended in both IBS patients and in controls 
(Table 8). No differences in energy intake or intake of macronutrients were 
seen between subgroups of IBS patients, based on IBS symptom severity, 
presence or absence of anxiety or depression, or the predominant bowel habit.  
 
Table 8. Intake of energy and macronutrients in subjects in Paper I, 
comparison made between IBS patients and an age-and gender-matched 
group from the general population (controls).  
 
When comparing the intake of vitamins and minerals between IBS patients 
and controls, the IBS patients reported lower intake of vitamin A, riboflavin, 
calcium, and potassium, and a higher intake of folate, vitamin C, vitamin E, 
and iron than the age- and gender-matched controls from the national survey.  
Paper I 
  
Energy and macronutrients Recommended 
intake according 
to NNR 2004 
IBS patients 
(n=187) 
Controls 
(n=374) 
p-value 
 
Energy (kcal ± SD) - 2037 ± 541 1973 ± 513 0.17 
Protein (E% ± SD) 10-20 17 ± 3 16 ± 2 0.007 
Fat (E% ± SD) 25-35 35 ± 7 34 ± 5 0.17 
Carbohydrates (E % ± SD) 50-60 47 ± 8 47 ± 5 0.64 
Dietary fibers (g/MJ* ± SD) 3 2.2 ± 0.7 2.0 ± 0.6 <0.001 
Alcohol (E% ± SD) <5 2.6 ± 3.2 3.1 ± 3.5 0.10 
The recommended intake (RI) is shown for women in the ages 31-60 years (as 74 % of the 
subjects were females and the mean age for the studied population was 40 years of age).     
*1 MJ ????????? 
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The mean intake of vitamins and minerals in IBS patients and control 
subjects were above the average requirements according to NNR 2004. 
However, when compared to the recommended intake (RI) according to NNR 
2004, both patients and controls reported intake of folate, vitamin D, and iron 
that were below the recommendations, whereas controls only had an intake 
below RI for vitamin E and the IBS population had a lower intake than RI for 
potassium (Figure 5). No differences in micronutrient intakes between 
subgroups of IBS patients, based on IBS symptom severity, presence or 
absence of anxiety or depression, or the predominant bowel habit were seen. 
 
Figure 5. Nutrient intake in IBS patients vs. the controls, in 
comparison with recommended intake according to NNR 2004.          
* p<0.05 IBS vs. controls. 
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We included 197 IBS patients (Rome III) in this study. In all, 84 % of the 
patients reported at least one food item to cause GI symptoms. The 
proportion of subjects that reported GI symptoms related to the different food 
groups are displayed in Table 9. On average, patients reported GI symptoms 
from 7.8 ± 8.3 (range 0-54) food items. 
 
Table 9. Food groups/constituents and related food items in Paper II and the 
proportion of patients reporting GI symptoms related to the different food 
groups. 
 
Patients that reported a higher number of food items causing GI symptoms, 
(as an indirect measure of more severe self-reported food intolerance) had 
more severe IBS symptoms (IBS-SSS; p=0.004) and more severe somatic 
symptoms in general (PHQ-15; p=0.03). However, there were no correlations 
between self-reported food intolerance (number of food items reported to 
cause GI symptoms) and anxiety, depression, GI-specific anxiety, body mass 
index or age. Women tended to report more food items responsible for their 
GI symptoms than men (p=0.06). IBS subtype based on the predominant 
bowel habit was not associated with number of food items causing 
symptoms. Lower quality of life in the IBSQOL domains sleep, energy, diet, 
social functioning, and physical status were significantly associated with a 
higher number of food items reported to cause GI symptoms. 
Food groups Foods reported to cause GI symptoms 
% patients 
reporting GI 
symptoms 
Incompletely 
absorbed 
carbohydrates 
Peach, cherries, plum, potato, pear, apple, apricot, nectarine, 
soy, peas, beans/lentils, peanuts, wheat flour, other flour 
(most commonly rye), milk, sour milk/yoghurt, cheese, 
chocolate, celery, melon, bananas, avocado, or dried fruit 
70 % 
Histamine-
releasing Egg, fish, tomato, shellfish, strawberries, orange, wine/beer 68 % 
Biogenic amines Cheese, fish, salami, tomato, chocolate, orange, wine/beer, bananas, avocado 58 % 
Benzoic acid and 
sulfites 
Sour milk/yoghurt, tomato, orange, lingonberry, wine/beer, 
dried fruit 56 % 
Fried and fatty 
foods  No food items were defined 52 % 
Lectin-containing Potato, soy, peas, beans/lentils, peanuts, wheat flour 49 % 
Capsaicin-
containing Cayenne/red pepper, chili/tabasco, bell pepper 42 % 
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Twenty IBS patients (Rome III; 19 females) with bloating as a predominant 
symptom started and completed this randomized, double-blind, placebo-
controlled cross-over study where the effect of ?-galactosidase (Nogasin®) 
on GI symptoms after intake of carbohydrate-rich meals was assessed (Figure 
6).  
 
Figure 6. Flow chart demonstrating the number of patients in the 
different phases of the study. 
 
 
 
 Invited to participate (n=62) 
No reply (n=13) 
Declined (n=24) 
Gave their consent (n=25) 
Drop-outs (n=5) 
Randomized (n=20) 
Placebo (n=10) 
Placebo (n=10) α-galactosidase (n=10) 
(n=10)(n=10) 
α-galactosidase (n=10) 
(n=10)(n=10) 
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The patients reported increasing severity of meal-related GI symptoms after 
the test meals, and significant effects of time were found for symptom ratings 
of gas, bloating, discomfort, distension, urgency to have a defecation, and 
abdominal pain (Figure 7 and 8). However, symptom ratings were not 
different between the test days when α-galactosidase (Figure 7) or placebo 
(Figure 8) was ingested before the meals.  
 
Furthermore, no significant differences were found between α-galactosidase 
or placebo for any of the GI symptoms assessed the day after the test days. 
 
A significant effect of time was found for both hydrogen (F=6.2, p<0.0001) 
and methane (F=1.7, p=0.044) concentrations in breath tests from baseline, 
but these changes in hydrogen and methane concentrations did not differ 
between α-galactosidase or placebo (Figure 9). 
 
 
Figure 7. GI symptoms (mean values) during the test day with α-
galactosidase. The arrows represent the time points for intake of the 
carbohydrate-rich meals. 
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Figure 8. GI symptoms (mean values) during the test day with 
placebo. The arrows represent the time points for intake of the 
carbohydrate-rich meals.  
 
 
Figure 9. Hydrogen and methane in expired air (mean values) during 
test days with intake of ?-galactosidase (enzyme) or placebo, 
respectively. 
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In this randomized, controlled, single-blind, parallel group study we screened 
84 patients with IBS according to Rome III criteria. Seventy-five patients 
were randomized to follow one of the two diets, and 67 patients completed 
the dietary intervention (Figure 10). 
 
Figure 10. Flow chart demonstrating the number of patients in the 
different phases of the study. 
 
The IBS symptom severity was reduced in both dietary intervention groups at 
the end of the study period compared to baseline, without any differences 
between the groups (p=0.72) (Figure 11). In line with this, the responder rate 
(IBS-????????????????????????????????????????????????????????????????????????
similar in both groups (Figure 12). When assessing the effect of the 
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interventions on the individual items of the IBS-SSS score, all items were 
improved in both groups at day 29 relative to baseline, and this reached 
statistical significance for some of the items (Figures 13 and 14). 
 
Figure 11. Comparison between baseline and at week 4 for severity 
scores (IBS-SSS) in the low FODMAPs diet group and the traditional 
IBS diet group.  
 
 
 
 
 
 
 
 
 
Figure 12. Responder rate at the end of treatment compared to 
baseline according to IBS-SSS reduction.  
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Figure 13. Ratings of the individual items of the IBS-SSS score in low 
FODMAPs diet.  
 
 
 
 
 
 
 
 
 
 
Figure 14. Ratings of the individual items of the IBS-SSS score in the 
traditional IBS diet.  
 
 
 
 
 
 
 
 
 
 
** *** *** 
**p< 0.01 
***p<0.001 
**p< 0.01 
***p<0.001 
*** ** ** ** 
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When comparing responders and non-responders in the two treatment groups, 
lower intake of FODMAPs at baseline (p=0.01), being older (p=0.05) and 
female (p=0.02) were associated with a positive response to the low 
FODMAPs group, whereas having non-constipated IBS (p=0.02) was 
associated with a positive response to the traditional IBS diet. 
At baseline both groups in Paper IV had similar intake of nutrients, including 
the intake of FODMAPs. However, during the last week of the intervention 
period, clear changes in the dietary intake were noted, both within the groups 
and between the groups. Most notably, the low FODMAPs group reduced 
their intake of FODMAPs, which was not the case in the traditional IBS diet 
group, indicating good adherence to the dietary advice. Unexpectedly, both 
groups substantially reduced their energy intake during the dietary 
intervention. We therefore compared the participants’ intake at the end of the 
intervention period to the Nordic Nutrition Recommendation 2012. Both 
groups reached the recommendations except for energy intake and intake of 
carbohydrates and dietary fibers which were low in both diet groups. The 
intake of carbohydrates and dietary fibers were significantly lower in the low 
FODMAPs group (Table 10). 
 
Table 10. Intake of energy and macronutrients during the dietary 
interventions in relation to recent Nordic Nutrition Recommendations (NNR 
2012). 
 
Energy and 
macronutrients 
Recommendations 
according NNR 2012 
Low FODMAPs 
diet during 
intervention 
(n=33) 
Traditional IBS 
diet during 
intervention 
(n=33) 
p-value 
between 
diets 
 
Energy (MJ) 22501 1658 1889 0.03 
Protein (E%) 10-20 18 16 0.67 
Fat (E%) 25-40 37 37 0.11 
Carbohydrates 
(E%) 
45-60 38 41 0.007 
Dietary fibers 
(g/MJ) 
3 2.2 2.6 0.003 
Alcohol (E%) <5 4 3 0.005 
1 Required energy= calculated the mean resting energy expenditure (155) based on age, sex 
and weight and multiplied with the average Physical Activity Level in the Nordic countries 
(PAL=1.6) 
*1 MJ ≈240 kcal 
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In the present thesis we have demonstrated that food is a central issue in the 
management of patients with IBS. In line with previous studies, we 
demonstrated that food-related GI symptoms in patients with IBS are very 
common; in fact the vast majority reported at least one food item that they 
consider to cause GI symptoms. Despite this, patients suffering from IBS do 
not seem to have a greater risk than the general population to develop nutrient 
deficiency and as a group they have a sufficient general nutrient intake. IBS 
patients often experience GI symptoms in relation to food intake and this 
self-reported food intolerance was demonstrated to be associated with more 
severe symptoms in general and with reduced quality of life. Many different 
food items from various food groups were reported to influence symptom 
generation in IBS patients, such as fatty/fried foods, histamine releasing 
foods, foods containing preservatives, foods rich in biogenic amines, and 
especially food rich in incompletely absorbed carbohydrates. Unfortunately, a 
simple approach to use a capsule with an enzyme, ?-galactosidase, that can 
digest carbohydrates and thereby facilitate their uptake and reduce 
fermentation of non-digestible carbohydrates, do not seem to alleviate 
symptoms related to food-intake with high amounts of incompletely absorbed 
carbohydrates. However, in the last paper in this thesis we demonstrated that 
providing IBS patients with dietary advice seem to be a good way to reduce 
GI symptoms, but that the recently developed low FODMAPs diet do not 
seem to be superior to traditional IBS dietary advice.  
 
When performing clinical research in general, it is important to have 
representative patient samples, or at least to be aware of which part of a 
certain disease population that you are studying. This is of relevance for the 
interpretation of the data and for the generalizability of results, and later for 
the potential implementation in clinical practice. In IBS studies performed at 
a specialized university-based clinic, selection bias is an obvious risk, as the 
majority of IBS patients are managed in primary care. Moreover, food and 
nutrition studies also per se carry a risk of selection bias, as patients who are 
more interested in food may be more willing to participate in such studies.  
In Papers I and II IBS patients were retrieved from treatment studies (156, 
157) and a pathophysiology study (31, 38) at the gastroenterology unit at 
Sahlgrenska University Hospital, where questionnaires used in these studies 
as part of the baseline assessment, were evaluated in the current papers. 
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These studies were multifactorial and had not food intake as a major focus 
which reduces the number of participants with special interest of food and 
therefore hopefully capture a mixed IBS population, even though the study 
was performed in a secondary/tertiary care setting. Moreover, at our 
dedicated unit with a special interest in functional GI disorders we accept all 
referrals for IBS, including self-referrals, which in previous publications on 
IBS have attracted a comparably representative IBS population with active 
problems (22, 30, 158). Therefore, for the purpose of these studies, i.e. to 
study food-related GI symptoms and nutrient intake in patients with current 
IBS symptoms, we believe that our recruitment approach was valid, and that 
we reached a fairly representative IBS population with active symptoms.  
In Paper III, our aim was to reach an IBS population with symptoms related 
to incompletely absorbed carbohydrates. Bloating, abdominal distension and 
other gas-related symptoms are prominent symptoms in relation to these food 
constituents (121, 122). Therefore, patients were recruited based on reports of 
gas-related symptoms in previous studies at our unit. However, several 
patients were reluctant to undergo the study mainly due to the two full day 
visits at the hospital, which meant that the patients had to take time off from 
work and also to eat foods regarded as being symptom triggers, which may 
have introduced a negative selection bias, and potentially excluded patients 
with prominent gas-related symptoms due to incompletely absorbed 
carbohydrates.  
In Paper IV, the participants were recruited from the gastroenterology 
outpatient clinics at three hospitals, and through advertisement in a local 
newspaper. During the recruitment phase several of the participants 
expressed their interest in food and their conviction of its importance in 
symptom generation in IBS, which was good for the commitment, required 
for the intervention, but may have introduced a selection bias. However, 
dietary interventions are only possible in patients with an interest in changing 
their diet, which therefore has to be the target group in such studies. 
Taken together, our study populations seem to be relevant for the research 
questions in the present thesis, even though we cannot generalize all findings 
to all subjects with IBS in the community.  
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As mentioned in the background, different ways of assessing nutrient intake 
are available, and all of these have potential problems (43). A food diary was 
used in Paper I and Paper IV. Underreporting of energy intake is common in 
dietary assessments which also imply underreporting of most nutrients (159-
163). Nutrient intake data are not absolute values as they are based on 
reported food consumption, which have a considerable error margin (164). In 
order to find out whether the intake of a particular nutrient is adequate, 
biochemical measurements and thorough individual dietary assessments are 
necessary (164), which were not done in the current papers. In our studies we 
used food diaries that are not affected by systematic errors to the same degree 
as e.g. FFQ. A food diary has the advantage to capture detailed information 
about food intake for a short period of time. On the other hand, reactivity bias 
can be a problem as patients may change their eating behavior or their 
habitual food choices as a consequence of the recording in real time (43). A 
possible way to reduce this bias may be to limit the number of days to 
register food intake. In our study we used four days, which we consider to be 
a reasonable compromise between capturing day-to-day variability in food 
intake, and putting too much burden on the subject.    
In our studies, comparisons with nutrient intake was done with either 
????????????????????????????????aper I, and in the thesis a comparison was 
made for data in P???????????????????????????????????????????????????????
used to define the intake of a nutrient that represents the average 
requirements for a defined group of individuals. RI of certain nutrients is 
used in planning diets for groups (164) and includes a safety margin of two 
standard deviations or more, i.e. the amount of nutrient that can meet the 
known requirement among practically all healthy individuals. 
 
 
In Paper I we investigated if the nutrient intake in patients with IBS differed 
from the general population in Sweden. The overall intake was similar, which 
was somewhat surprising to us, as it is well known based on clinical 
experience that patients often complain of the adverse effects of various food 
items on GI symptoms, and many patients exclude different food items from 
their diet (165). One possible explanation for these seemingly discrepant 
findings can be that IBS patients shift their intake from foods considered to 
cause symptoms to a larger intake of less offending food items. This will 
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yield a limited variety of food items in the diet, but without necessarily 
affecting nutrient composition or energy intake. Our finding with normal 
nutrient intake in IBS patients as a group is in line with some (68, 166-168), 
but not all (169, 170) previous studies on this topic. Different methods of 
assessment of nutrient intake, different study populations, as well as regional 
differences may explain the discrepancy between studies.  
In order to minimize investigator bias, the analyses of the food diaries in 
Papers I and IV were done after all data were collected, with only the 
??????????????????????????????????????????? in order to minimize impact from 
personal opinions or preconceptions of the included patients.  
In Paper IV we used the food diaries to detect (expected) nutritional 
???????????????????????????????????????????????????????????????????????????????????
FODMAPs group significantly lowered their intake of FODMAPs as 
intended, which was the case in both responders and non-responders to this 
intervention. On the other hand, the patients who followed the traditional IBS 
dietary advice did not reduce their intake of FODMAPs. An unwanted 
finding in this study was the considerable decrease in energy intake in both 
the low FODMAPs group and in the traditional IBS diet group during the 
intervention period. This decrease implicate that patients eliminate food items 
from their diet but do not replace them appropriately with adequate amounts 
of alternative foods, which in the long run may lead to involuntary weight 
loss and development of nutrient deficiency. This unexpected and unwanted 
finding highlights the importance of monitoring nutrient intake when dietary 
advice is given to patients.  
 
 
More than 80 % of patients in Paper II reported GI symptoms related to food 
intake, which is even higher than in previous studies (46-48). This may partly 
be due to the fact that we included a larger number of food items in our 
questionnaire than in some of the previous studies ? reporting only one of 
these as being related to GI symptoms was enough to include the patient in 
the group with self-reported food intolerance. However, regardless of what 
the correct proportion of patients reporting an association between food and 
symptoms is, it can be concluded that food-related GI symptoms are very 
common in IBS. Moreover, our study also demonstrated that self-reported 
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food intolerance was associated with a certain clinical phenotype within the 
IBS population with more severe symptoms and reduced quality of life. 
Foods do not only consist of energy and nutrients but also different food 
constituents with possible effects on symptoms. In Paper II we explored 
potential associations between some of these constituents and the reported 
symptoms from foods containing these. Fatty/fried food are one food group 
that was reported to be associated with GI symptoms in this study, as 52 % 
reported GI symptoms from this food group. Fat intake enhances the 
gastrocolonic response and increase visceral sensitivity in IBS patients (171, 
172), but also increase gas retention (85), so different mechanisms may 
explain this association. Incompletely absorbed carbohydrates (or 
FODMAPs) were also frequently reported to be associated with GI 
symptoms, which makes it logical to advice patients to reduce dietary intake 
of FODMAPS. There were also some new associations proposed in our 
study, which should be considered more as hypothesis generating proposals, 
such as the associations between GI symptoms and foods rich in biogenic 
amines, foods containing preservatives, capsaicin- and lectin-containing 
foods, and foods considered to be histamine-releasing.  
Almost all foods included in our questionnaire contributed to some self-
reported GI symptoms, and of course it is making it too easy to say that these 
constituents are the sole explanation of symptom generation. It is most likely 
a combination of many different aspects of food that causes symptoms; 
energy content, volume of meal, content of fat, incompletely absorbed 
carbohydrates, dietary fibers, histamine-releasing properties of foods, 
contents of lectins, biogenic amines, capsaicin, and preservatives etc. All of 
these have probable individual effects on the GI tract and food rarely only 
consist of one single item, but is a combination of several food items in 
connection with mental state, coping strategies, childhood, heritage, what you 
ate yesterday and so forth. The biopsychosocial model proposed to be of 
relevance for IBS (173) in general, can probably also be applied to the effects 
of food on GI symptom generation in IBS.  
 
 
An appealing method to reduce symptoms would be to take a pill together 
with offending foods in order to eliminate food-related symptoms such as 
bloating, abdominal distension and flatulence. Unfortunately, we could not 
find evidence for an effective alleviation of GI symptoms with capsules 
containing the enzyme ?-galactosidase administered in combination with 
meals rich in incompletely absorbed carbohydrates. This is at odds with some 
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previous trials (126-129), but these were not performed in adults with IBS. 
Moreover, our study design only made it possible to study the effect of the 
enzyme during one day. A cumulative effect may be possible if the enzyme is 
ingested daily for several days, but this remains to be proven. Moreover, the 
enzyme has effect only on incompletely absorbed carbohydrates, and more 
specifically certain oligosaccharides. Negative effects from other food 
constituents are not affected by this enzyme.  
 
In Paper IV we demonstrated that dietary advice lead to reduced IBS 
symptoms over four weeks. However, we could not demonstrate that the very 
popular and frequently advocated low FODMAPs diet was better than 
traditional IBS dietary advice. This may seem to be at odds with recent 
evidence from clinical trials (64, 96, 97, 123), but previous studies have not 
had an active comparator, or have used a non-randomized trial design. 
Therefore, our trial is the first study comparing a low FODMAPs diet with an 
active comparator in a randomized, single-blinded design. Our interpretation 
of the study results is that there probably are elements in both diets that are 
beneficial, and we propose that future studies try to combine elements from 
both diets in dietary advice to IBS patients. 
Moreover, recent evidence suggests that there may be adverse effects of a 
low FODMAPs diet on the gut microbiota composition (97, 104). Therefore 
strict use of this diet should probably only be used short term to eliminate 
current symptoms and only exceptionally as a continuous long term dietary 
change (104). Besides, it is imperative that this elimination is under 
supervision from a dietitian (or another person with good knowledge about 
FODMAPs). Currently, a strict FODMAPs exclusion diet should not last 
more than 2-8 weeks, based on the potential adverse effects on microbiota 
composition in the colon, and as no long-term studies are available. A 
gradual reintroduction of FODMAPs is advocated, but how this should be 
done and the effectiveness of such an approach has not yet been studied (93, 
123). Further, a low FODMAPs diet should be completely avoided in 
asymptomatic persons. FODMAPs stimulate the growth of the beneficial 
bifidobacteria (97) and are also substrate for bacteria to promote production 
of short-chain fatty acids. These fatty acids have positive effect on the 
immune system and are the most important source of energy to the colonic 
epithelial cells and may be protective for cancer development in the colon 
(174) .  
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For future dietary intervention trials in IBS, we consider that it is important to 
individually assess the nutrient intake, as it is common that IBS sufferers 
alter their food intake to control symptom intensity and frequency (66). It 
could be useful to determine the IBS patients’ total energy intake, if they 
have large intake of certain possibly offending foods such as fatty foods, 
coffee, spices, or incompletely absorbed carbohydrates (in e.g. onion, beans, 
and apples), and of course to assess the intake of micronutrients and look for 
a potential risk of developing deficiencies. It is necessary to establish a 
partnership between the patient and the practitioner to come up with 
individual solutions to avoid irregular eating habits, unfavorable cooking 
methods and symptom generating choices of food items. It is imperative to 
listen to the patients’ narratives about their experiences and perceived 
symptoms to different foods to adequately be able to optimize treatment 
routines. An individualized dietary treatment approach for IBS should be 
tested in prospective trials. 
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The present thesis has shown that in spite of food-related GI symptoms being 
reported by the majority of IBS patients, as a group they generally have an 
adequate nutrient intake. Moreover, the self-reported food intolerance that 
was seen in 84 % of our IBS patients was associated with more severe 
symptoms in general, which makes dietary adjustments an attractive 
therapeutic approach. However, as the food items reported to cause GI 
symptoms differ between individuals it seems essential to assess nutrient 
intake on an individual basis, and to investigate which food items the patient 
consider to cause symptoms in order to optimize personalized dietary advice. 
We investigated different approaches to influence negative effects of dietary 
constituents, and we did not find any evidence in support of a clinically 
beneficial effect of the enzyme ?-galactosidase in IBS, but dietary advice 
seem to be an efficient tool to reduce symptoms. Specifically, both the 
traditional IBS dietary advice and the recent development of a low 
FODMAPs diet reduced symptom severity, and future studies should 
investigate if elements from these diets can be combined in dietary advice to 
patients with IBS.  
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Future studies should focus on developing more accurate ways to record food 
intake that are simple and applicable both for the patients as well as for 
investigators. It would also be preferable to study eating behavior in IBS in 
greater detail, i.e. where, how, when and why? 
Identify patients with IBS with poor nutrient intake, and investigate the 
symptom patterns and response to dietary interventions in this group of 
patients.  
The effects of food constituents on GI symptoms in IBS need to be examined 
further through challenge tests in prospective studies. 
Future studies should aim at further improving strategies for providing 
dietary advice to patients with IBS, potentially combining elements from 
different strategies and ideally customize dietary advice for different patient 
populations. 
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